查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1678486

美國皮膚科藥物市場：市場規模、佔有率、趨勢分析（按治療方法、類型、給藥途徑、藥物類別、分銷管道和地區）、細分市場預測（2025-2030 年）

U.S. Dermatological Drugs Market Size, Share & Trends Analysis Report By Therapy (Acne, Psoriasis), By Type (Prescription, Over-the-Counter), By Route Of Administration, By Drug Class, By Distribution Channel, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國皮膚病藥物市場的成長與趨勢：

根據 Grand View Research, Inc. 的一份新報告，美國皮膚病治療市場預計到 2030 年將達到 144.8 億美元，2025 年至 2030 年期間的複合年成長率為 9.7%。

這一市場的成長得益於針對慢性皮膚病的新型治療方法的出現，以及痤瘡、乾癬等皮膚問題的日益普遍。此外，人們越來越意識到皮膚健康在整體健康中的重要性，這也促進了市場的成長。

此外，對研發的大量投資促進了新藥的開發，這些新藥可在櫃檯購買，使治療更加容易獲得，從而促進了整體成長。最近，幾家製藥和消費者保健公司已獲得美國FDA核准，批准其生產基於治療嚴重皮膚病和改善患者預後的創新產品。

新型藥物輸送系統的出現以及市場參與企業對皮膚病學領域合作研究的日益關注也在市場成長中發揮關鍵作用。預計在預測期內，大量個人尋求可負擔的治療、零售藥局提供的非處方藥、以及提供快速送貨和網上銷售等新服務的零售商不斷擴大的產品範圍將為該市場提供有利的成長機會。

美國皮膚科藥物市場：概覽

  • 到 2024 年，乾癬將在治療領域佔據主導地位，佔有率超過 35.0%。這是因為大量患者尋求有效的乾癬治療，而市場參與企業正專注於提供新穎的治療方法。
  • 在美國，預計預測期內皮膚科痤瘡藥物將以顯著的複合年成長率成長。
  • 到 2024 年，處方箋皮膚病藥物將佔據最大的市場佔有率，達到 77.5%。預計預測期內場外交易（OTC）部分將顯著成長。
  • 局部用藥以其更好的患者體驗、患者友善的給藥系統和易於使用等優勢，在 2024 年佔據了美國皮膚病藥物市場的主導地位，收入佔有率為 60.0%。預計在預測期內，腸外藥物部門的複合年成長率最快，為 10.7%。
  • 研發投入的不斷增加、許多新藥和新產品的核准以及零售藥局的便利性都促進了美國皮膚病藥物市場的成長。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

第 3 章美國皮膚病藥物市場：促進因素、趨勢與範圍

  • 市場聯動展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTEL 分析

第 4 章。美國皮膚病藥物市場：按治療方法類型的估計和趨勢分析

  • 治療方法的市場佔有率（2024 年和 2030 年）
  • 治療方法儀表板
  • 市場規模預測及治療方法趨勢分析（2018-2030）
  • 粉刺
    • 痤瘡市場（2018-2030）
  • 乾癬
    • 乾癬市場（2018-2030）
  • 酒糟
    • 酒糟市場（2018-2030）
  • 脫髮症
    • 脫髮症市場（2018-2030）
  • 其他
    • 其他市場（2018-2030）

第 5 章：美國皮膚病藥物市場：按類型分類的估計和趨勢分析

  • 按類型分類的市場佔有率（2024 年和 2030 年）
  • 按類型分類的儀表板
  • 按類型分類的市場規模預測及趨勢分析（2018-2030）
  • 處方箋
    • 處方藥市場（2018-2030）
  • 場外交易（OTC）
    • 非處方藥 (OTC) 市場（2018-2030 年）

第6章美國皮膚病藥物市場：按給藥途徑的估計和趨勢分析

  • 按管理途徑分類的市場佔有率（2024 年和 2030 年）
  • 管理路線儀表板
  • 依管理途徑分類的市場規模預測及趨勢分析（2018-2030 年）
  • 局部給藥
    • 局部遞送市場（2018-2030）
  • 口服
    • 口服給藥市場（2018-2030）
  • 腸外給藥
    • 腸外給藥市場（2018-2030）

第 7 章。美國皮膚科藥物市場：按藥物類別的估計和趨勢分析

  • 按藥物類別分類的市場佔有率（2024 年和 2030 年）
  • 藥品類別儀表板
  • 依藥物類別分類的市場規模預測及趨勢分析（2018-2030年）
  • 皮質類固醇
    • 皮質類固醇市場（2018-2030）
  • 類視色素
    • 類視色素市場（2018-2030）
  • 抗生素
    • 抗生素市場（2018-2030）
  • 抗真菌藥物
    • 抗真菌藥物市場（2018-2030）
  • Calcineurin抑制劑
    • Calcineurin抑制劑市場（2018-2030）
  • 其他
    • 其他市場（2018-2030）

第 8 章：美國皮膚病藥物市場：按分銷管道進行的估計和趨勢分析

  • 按分銷管道分類的市場佔有率（2024 年和 2030 年）
  • 分銷通路儀表板
  • 按分銷管道分類的市場規模預測及趨勢分析（2018-2030 年）
  • 醫院藥房
    • 醫院藥局市場（2018-2030）
  • 零售藥局
    • 零售藥局市場（2018-2030）
  • 其他
    • 其他市場（2018-2030）

第9章 競爭格局

  • 參與企業概況
  • 公司市場地位分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • AbbVie Inc.
    • Pfizer Inc.
    • GSK plc.
    • LEO Pharma A/S
    • Sun Pharmaceutical Industries Ltd.
    • GALDERMA
    • Amgen Inc.
    • Johnson &Johnson Services Inc.
    • Novartis AG
    • Eli Lilly and Company
    • Almirall, SA
    • Bausch Health Companies Inc.
Product Code: GVR-4-68040-512-3

U.S. Dermatological Drugs Market Growth & Trends:

The U.S. dermatological drugs market size is anticipated to reach USD 14.48 billion by 2030, expanding at a CAGR of 9.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is driven by the availability of novel treatments designed for chronic skin diseases and the increasing prevalence of skin problems such as acne, psoriasis, and others. Increasing awareness regarding the significance of skin health in overall well-being also contributes to the growth.

Moreover, significant investments in research and development lead to new medications, and the availability of over-the-counter products makes treatments more accessible, contributing to overall growth. In recent years, multiple pharmaceutical and consumer healthcare companies have received U.S. FDA approvals for innovation-based products developed to treat severe skin conditions and enhance patient outcomes.

The emergence of new drug delivery systems and key market participants turning to collaboration-based research efforts in dermatology have also played vital roles in the market's growth. The large number of individuals seeking affordable treatments, the availability of over-the-counter products across retail pharmacies, and retailer service expansions with novel offerings such as fast delivery and online distribution are projected to add lucrative growth opportunities for this market over the forecast period.

U.S. Dermatological Drugs Market Report Highlights:

  • Psoriasis dominated the therapy segment with more than 35.0% share in 2024, owing to many individuals seeking effective treatment for psoriasis and the focus of market participants on the delivery of novel therapies
  • Dermatological drugs for acne are expected to grow at a significant CAGR in the U.S. over the forecast period
  • The prescription-based dermatological drugs held the largest market share, 77.5%, in 2024. The over-the-counter segment is anticipated to witness significant growth over the forecast period
  • Topical administration dominated the U.S. dermatological drugs market, with a revenue share of 60.0% in 2024, owing to patients' treatment experiences, patient-friendly delivery systems, and ease of use. The parenteral administration segment is expected to witness the fastest CAGR of 10.7% over the forecast period
  • Increasing investments in research and development, approvals received for numerous novel therapies and products, and convenience offered by retail pharmacies are contributing to the growth of the U.S. dermatological drugs market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
    • 1.2.2. Type
    • 1.2.3. Route of Administration
    • 1.2.4. Drug Class
    • 1.2.5. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Dermatological Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Dermatological Drugs Market: Therapy Estimates & Trend Analysis

  • 4.1. Therapy Market Share, 2024 & 2030
  • 4.2. Therapy Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 4.4. Acne
    • 4.4.1. Acne Market, 2018 - 2030 (USD Million)
  • 4.5. Psoriasis
    • 4.5.1. Psoriasis Market, 2018 - 2030 (USD Million)
  • 4.6. Rosacea
    • 4.6.1. Rosacea Market, 2018 - 2030 (USD Million)
  • 4.7. Alopecia
    • 4.7.1. Alopecia Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Dermatological Drugs Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Prescription
    • 5.4.1. Prescription Market, 2018 - 2030 (USD Million)
  • 5.5. Over-the-Counter (OTC)
    • 5.5.1. Over-the-Counter (OTC) Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Dermatological Drugs Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2030
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Topical Administration
    • 6.4.1. Topical Administration Market, 2018 - 2030 (USD Million)
  • 6.5. Oral Administration
    • 6.5.1. Oral Administration Market, 2018 - 2030 (USD Million)
  • 6.6. Parenteral Administration
    • 6.6.1. Parenteral Administration Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Dermatological Drugs Market: Drug Class Estimates & Trend Analysis

  • 7.1. Drug Class Channel Market Share, 2024 & 2030
  • 7.2. Drug Class Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 7.4. Corticosteroids
    • 7.4.1. Corticosteroids Market, 2018 - 2030 (USD Million)
  • 7.5. Retinoids
    • 7.5.1. Retinoids Market, 2018 - 2030 (USD Million)
  • 7.6. Antibiotics
    • 7.6.1. Antibiotics Market, 2018 - 2030 (USD Million)
  • 7.7. Antifungals
    • 7.7.1. Antifungals Market, 2018 - 2030 (USD Million)
  • 7.8. Calcineurin Inhibitors
    • 7.8.1. Calcineurin Inhibitors Market, 2018 - 2030 (USD Million)
  • 7.9. Others
    • 7.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. U.S. Dermatological Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 8.1. Distribution Channel Market Share, 2024 & 2030
  • 8.2. Distribution Channel Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 8.4. Hospital Pharmacies
    • 8.4.1. Hospital Facilities Market, 2018 - 2030 (USD Million)
  • 8.5. Retail Pharmacies
    • 8.5.1. Retail Facilities Market, 2018 - 2030 (USD Million)
  • 8.6. Ohers
    • 8.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. AbbVie Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Pfizer Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. GSK plc.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. LEO Pharma A/S
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Sun Pharmaceutical Industries Ltd.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. GALDERMA
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Amgen Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Johnson & Johnson Services Inc.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Novartis AG
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Eli Lilly and Company
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. Almirall, S.A
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives
    • 9.5.12. Bausch Health Companies Inc.
      • 9.5.12.1. Overview
      • 9.5.12.2. Financial Performance
      • 9.5.12.3. Product Benchmarking
      • 9.5.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. dermatological drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 4 U.S. dermatological drugs market, by type, 2018 - 2030 (USD Million)
  • Table 5 U.S. dermatological drugs market, by route of adminstration, 2018 - 2030 (USD Million)
  • Table 6 U.S. dermatological drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 U.S. dermatological drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S. dermatological drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapy and type outlook (USD Million)
  • Fig. 10 Route of administration & drug class outlook (USD Million)
  • Fig. 11 Distribution channel outlook (USD Million)
  • Fig. 12 Competitive landscape
  • Fig. 13 U.S. dermatological drugs market dynamics
  • Fig. 14 U.S. dermatological drugs market: Porter's five forces analysis
  • Fig. 15 U.S. dermatological drugs market: PESTLE analysis
  • Fig. 16 U.S. dermatological drugs market: Therapy segment dashboard
  • Fig. 17 U.S. dermatological drugs market: Therapy market share analysis, 2024 & 2030
  • Fig. 18 Acne market, 2018 - 2030 (USD Million)
  • Fig. 19 Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 20 Rosacea market, 2018 - 2030 (USD Million)
  • Fig. 21 Alopecia market, 2018 - 2030 (USD Million)
  • Fig. 22 Others market, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. dermatological drugs market: Type segment dashboard
  • Fig. 24 U.S. dermatological drugs market: Type market share analysis, 2024 & 2030
  • Fig. 25 Prescription market, 2018 - 2030 (USD Million)
  • Fig. 26 Over-the-Counter (OTC) market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. dermatological drugs market: Route of administration segment dashboard
  • Fig. 28 U.S. dermatological drugs market: Route of administration market share analysis, 2024 & 2030
  • Fig. 29 Topical administration market, 2018 - 2030 (USD Million)
  • Fig. 30 Oral administration market, 2018 - 2030 (USD Million)
  • Fig. 31 Parenteral administration market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. dermatological drugs market: Drug class segment dashboard
  • Fig. 33 U.S. dermatological drugs market: Drug class market share analysis, 2024 & 2030
  • Fig. 34 Corticosteroids market, 2018 - 2030 (USD Million)
  • Fig. 35 Retinoids market, 2018 - 2030 (USD Million)
  • Fig. 36 Antibiotics market, 2018 - 2030 (USD Million)
  • Fig. 37 Antifungals market, 2018 - 2030 (USD Million)
  • Fig. 38 Calcineurin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 39 Others market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. dermatological drugs market: Distribution channel segment dashboard
  • Fig. 41 U.S. dermatological drugs market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 42 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 43 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 44 Others market, 2018 - 2030 (USD Million)
  • Fig. 45 Company categorization
  • Fig. 46 Company market position analysis
  • Fig. 47 Strategic framework